Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Martin-Romano P, Ammari S, El-Dakdoukti Y, Baldini C, Varga A, Vuagnat P, Angevin E, Bahleda R, Gazzah A, Champiat S, Michot JM, Postel-Vinay S, Marabelle A, Soria JC, Boige V, Malka D, Ducreux M, Massard C, Hollebecque A. Martin-Romano P, et al. Among authors: vuagnat p. Eur J Cancer. 2020 Sep;137:117-126. doi: 10.1016/j.ejca.2020.06.030. Epub 2020 Aug 2. Eur J Cancer. 2020. PMID: 32755794
Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma.
Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M. Ploquin A, et al. Among authors: vuagnat p. Case Rep Oncol. 2015 Oct 22;8(3):447-50. doi: 10.1159/000441414. eCollection 2015 Sep-Dec. Case Rep Oncol. 2015. PMID: 26600777 Free PMC article.
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.
Martin-Romano P, Castanon E, Ammari S, Champiat S, Hollebecque A, Postel-Vinay S, Baldini C, Varga A, Michot JM, Vuagnat P, Marabelle A, Soria JC, Ferté C, Massard C. Martin-Romano P, et al. Among authors: vuagnat p. Cancer Med. 2020 Apr;9(8):2643-2652. doi: 10.1002/cam4.2797. Epub 2020 Feb 19. Cancer Med. 2020. PMID: 32074405 Free PMC article.
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: vuagnat p. Eur J Cancer. 2020 Apr;129:71-79. doi: 10.1016/j.ejca.2020.01.013. Epub 2020 Mar 3. Eur J Cancer. 2020. PMID: 32143106
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
Laparra A, Kfoury M, Champiat S, Danlos FX, Martin-Romano P, Simonaggio A, Baldini C, Vuagnat P, Mateus C, Voisin AL, Albiges L, Besse B, Even C, Robert C, Laghouati S, Massard C, Marabelle A, Lambotte O, Michot JM. Laparra A, et al. Among authors: vuagnat p. Ann Oncol. 2021 Jul;32(7):936-937. doi: 10.1016/j.annonc.2021.04.006. Epub 2021 Apr 15. Ann Oncol. 2021. PMID: 33865965 Free article. No abstract available.
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors.
Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, Garcia de Herreros M, Vidal Tocino R, Longo-Muñoz F, El Dakdouki Y, Martín-Romano P, Gaba L, Saurí T, Oliveres H, Castañón E, Garcia-Carbonero R, Besse B, Massard C, Mezquita L, Hollebecque A. Auclin E, et al. Among authors: vuagnat p. Cancers (Basel). 2021 Jul 27;13(15):3776. doi: 10.3390/cancers13153776. Cancers (Basel). 2021. PMID: 34359675 Free PMC article.
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Hajem S, Ederhy S, Champiat S, Troalen F, Nolin-Lapalme A, Berhoune M, Cauquil C, Martin-Romano P, Baldini C, Laparra A, Vuagnat P, Hollebecque A, Mateus C, Besse B, Naltet C, Robert C, Marabelle A, Massard C, Lambotte O, Michot JM. Hajem S, et al. Among authors: vuagnat p. Eur J Cancer. 2021 Nov;157:383-390. doi: 10.1016/j.ejca.2021.08.045. Epub 2021 Sep 24. Eur J Cancer. 2021. PMID: 34571335
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: vuagnat p. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0. J Exp Clin Cancer Res. 2022. PMID: 35794623 Free PMC article. Clinical Trial.
56 results